DolPHIN2 |

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

image source: pexels

The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy

The team at the Infectious Diseases Institute, Kampala

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

How we work

About DolPHIN 2

Read about the challenges that the DolPHIN 2 project seeks to address and why.

The DolPHIN 2 Consortium

Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.

Community Voices

Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.

Resources

03 Dec 2019

HIV on Trial

Meet our research team, hear from some of our research participants and learn more about the DolPHIN story so far.

Video

28 Nov 2019

They become strong when they see me doing this

Jackie Kyeyune, a peer mother living with HIV, discusses how she uses her lived experience to support and inspire the DolPHIN 2 trial participants.

Video

28 Nov 2019

Trial Management at the Ugandan site

Dr Kenneth Kintu, trial manager at the IDI site, discusses the challenges and rewards of the study, and his hopes for the future

Video

28 Nov 2019

All Hands on Deck

Study Paediatrician Jesca Nakibuka describes the importance of a multidisciplary approach in the DolPHIN 2 clinical study

Video

View all Resources

News

The Ugandan Team Celebrates World Breastfeeding Week

08 Aug 2019

DolPHIN-2 presents primary outcome analysis at CROI 2019

05 Mar 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

20 Jun 2018

View all News and Events

@UoLDolPHIN2 on Twitter

RT @UNAIDS: Are you living with or affected by HIV? Here’s what you need to know about #COVID19 and HIV … https://t.co/NkRQ7MPqpy

8 hours 44 min ago

RT @EDCTP: Springer Nature has made SARS-CoV-2, COVID-19 and related research free. You can access the latest research here:… https://t.co/sifGph7u2c

2 weeks 6 hours ago

RT @justinchiong: Findings from the @UoLDolphin2 trial reported here #dolutegravir #DTG #HIV https://t.co/VZRBzVppVd

2 weeks 22 hours ago

RT @CatrionaWaitt: The delay between drug licensing and having appropriate data for pregnancy and lactation is too long. This report s… https://t.co/ZTTKD10uWI

2 weeks 22 hours ago

RT @hivinteractions: We have added an official twitter account for the COVID-19 website. @covidDDIs Please give it a follow for updates to the website.

2 weeks 4 days ago

RT @KimScarsi: Reassuring data from Dr. Rena Patel @UW, confirming no detrimental drug-drug interaction between dolutegravir-based… https://t.co/bKhCirwscG

3 weeks 1 day ago

The IMPAACT network shared their #pregnancy data at #CROI2020 today #DTG #HIV https://t.co/95H3XcI9Ah

3 weeks 2 days ago

RT @EpiBiostats_UCT: Postpartum weight changes in women initiating DTG https://t.co/XuMuwfv0jI (with @UoLDolphin2 )

3 weeks 2 days ago

Special session on COVID19 from #CROI2020 now publicly available https://t.co/HArY7jaVW2

3 weeks 2 days ago

RT @profchloeorkin: Scully: ‘Equal is not the same ! Sex specific demands such as pregnancy and maternal antibodies affect the immune r… https://t.co/19RAghB0hs

3 weeks 3 days ago

RT @profchloeorkin: How can we improve in recruiting women: a roadmap below. In this brilliant talk Scully says ‘These steps are not e… https://t.co/TidfFAthWI

3 weeks 3 days ago

Great presentation from Eileen Scully advocating the inclusion of pregnant and breast feeding women in trials #CROI2020

3 weeks 3 days ago

The D2 Consortium

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.

DolPHIN2

Search

How we work

About DolPHIN 2

The DolPHIN 2 Consortium

Community Voices

Resources

HIV on Trial

They become strong when they see me doing this

Trial Management at the Ugandan site

All Hands on Deck

News

The Ugandan Team Celebrates World Breastfeeding Week

DolPHIN-2 presents primary outcome analysis at CROI 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

@UoLDolPHIN2 on Twitter

The D2 Consortium

University of Liverpool

Liverpool School of Tropical Medicine

Infectious Diseases Institute

University of Cape Town

Radboud University Medical Centre

Unitaid

Contact us

Follow us